Mablytics is a preclinical-stage biotechnology company developing immunotherapies that are precisely delivered by means of a novel target. Recent studies have demonstrated highly restricted expression of the novel target in normal tissues, but overexpression in certain cancers. Immunotherapies directed at this target have the potential for highly effective treatment with low toxicity. With the discovery of the unique expression of this target, along with identifying predictive biomarkers that determine the likelihood of benefit or toxicities from potential therapies, Mablytics is opening the door to a more potent and yet safer immunotherapy. Ahead, patients at risk for having this protein can be identified and treatment of particular cancers can be optimized across patient groups. A new generation of patients will benefit by having targeted therapies selectively delivered to tumor cells across multiple cancer types, all with minimal effects on non-cancerous cells.